Racial differences in respiratory-related neonatal mortality among very low birth weight infants

Journal of Pediatrics

Volumn 136, Issue 4, 2000, Pages 454-459

  Ranganathan, Deepa ^a   Wall, Stephen ^a   Khoshnood, Babak ^a   Singh, Jaideep K ^a   Lee, Kwang Sun ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN MORTALITY; PRIORITY JOURNAL; RACE; RACE DIFFERENCE; RESPIRATORY DISTRESS; VERY LOW BIRTH WEIGHT;

EID: 0033914221     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(00)90007-6     Document Type: Article

References (30)

1. 1. Guyer B, Martin JA, MacDorman MF, Anderson RN, Strobino DM. Annual summary of vital statistics. Pediatrics 1997;100:905-18.
2. 2. Malloy MH, Hartford RB, Kleinman JC. Trends in mortality caused by respiratory distress syndrome in the United States, 1969-83. Am J Public Health 1987;77:1511-4.
3. 3. Singh GK, Yu SM. Infant mortality in the United States: trends, differentials, and projections, 1950 through 2010. Am J Public Health 1995;85:957-64.
4. 4. Wegeman ME. Annual summary of vital statistics-1990. Pediatrics 1991; 88:1081-92.
5. 5. Lee KS, Khoshnood B, Wall S, Chang Y, Hsieh HL, Singh JK. Trend in mortality from respiratory distress syndrome in the United States, 1970-1995. J Pediatr 1999;134:434-40.
6. 6. O'Shea TM, Preisser JS, Klinepeter KL, Dillard RG. Trends in mortality and cerebral palsy in a geographically based cohort of very low birth weight neonates born between 1982 to 1994. Pediatrics 1998;101:642-7.
7. 7. Hamvas A, Wise PH, Yang RK, Wampler NS, Noguchi A, Maurer MM, et al. The influence of the wider use of surfactant therapy on neonatal mortality among blacks and whites. N Engl J Med 1996;334:1635-40.
8. 8. National Center for Health Statistics. 1985, 1988 and 1991 birth cohort linked birth and infant death data set. Hyattsville (MD): Centers for Disease Control and Prevention, Department of Health and Human Services, January and February 1995 and May 1996. (CD-ROM series 20, no. 2, 4 and 7).
9. 9. Technical Appendix, Mortality File. National Center for Health Statistics. 1985, 1988 and 1991 birth cohort linked birth and infant death data set. Hyattsville (MD): Centers for Disease Control and Prevention, Department of Health and Human Services.
10. 10. The International Classification of Diseases, 9th rev. Clinical modifications, ICD-9-CM. 4th ed. Vols 1, 2, 3. New York: McGraw-Hill; 1994.
11. 11. Hosmer D Jr, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, Inc; 1989.
12. 12. SAS Institute Inc. SAS/STAT software: CALIS and LOGISTIC procedures, release 6.04 ed. Cary (NC): SAS Institute, Inc; 1990 (SAS technical report P-200).
13. 13. Long W, Corbet A, Cotton R, Courtney S, McGuiness G, Walter D, et al. A controlled trial of synthetic surfactants in infants weighing 1250g or more with RDS. N Engl J Med 1991; 325:1696-703.
14. 14. Soll RF, Hoekstra RE , Fangman JJ, Corbet AJ, Adams JM, James S, et al. Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of RDS. Pediatrics 1990;85:1092-102.
15. 15. Speer CP, Robertson B, Curstedt T, Halliday LH, Compagnone D, Gefeller O, et al. Randomized European multicenter trial of surfactant replacement therapy for severe RDS: single versus multiple doses of Curosurf. Pediatrics 1992;89:13-20.
16. 16. Horbar JD, Wright EC, Onstad L, and the Members of the NICHD Neonatal Research Network. Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601-1300g at birth. Pediatrics 1993; 92:191-6.
17. 17. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality and resource use in newborn infants weighing 500-1500g. N Engl J Med 1994;330:1476-80.
18. 18. Palta M, Weinstein MR, McGuiness G, Gabbert D, Brady W, Peters ME. A population study: morbidity and mortality after availability of surfactant therapy. Arch Pediatr Adolesc Med 1994;148:1295-301.
19. 19. Farrell PM, Wood RE. Epidemiology of hyaline membrane disease in the United States: analysis of national mortality statistics. Pediatrics 1976;58:167-76.
20. 20. CDC. Differences in infant mortality between blacks and whites-United States, 1980-1991. MMWR 1994;43: 288-9.
21. 21. Fujikura T, Froehlich LA. The influence of race and other factors on pulmonary hyaline membranes. Am J Obstet Gynecol 1966;95:572-8.
22. 22. Hulsey TC, Alexander GR. Hyaline membrane disease: the role of ethnicity and maternal risk characteristics. Am J Obstet Gynecol 1993;168:572-6.
23. 23. Ross S, Naeye RL. Racial and environmental influences on fetal lung maturation. Pediatrics 1981;68:790-5.
24. 24. Collaborative group of antenatal steroid therapy: effect of antenatal dexamethasone administration on the prevention of RDS. Am J Obstet Gynecol 1981;141:276-87.
25. 25. Crowley P, Chalmers I, Keirse MJNC. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br J Obstet Gynecol 1990;97:11-25.
26. 26. Maher JE, Cliver SP, Goldenberg RL, Davis RO, Cooper RL. The effect of corticosteroid therapy in the very premature infant. Am J Obstet Gynecol 1994;170:869-73.
27. 27. Avery ME. The argument for prenatal administration of dexamethasone to prevent RDS. J Pediatr 1984;104:240.
28. 28. Farrell EE, Silver RK, Kimberlin LV, Wolf ES, Dusik JM. Impact of antenatal dexamethasone administration on respiratory distress syndrome in surfactant-treated infants. Am J Obstet Gynecol 1989;161:628-33.
29. 29. Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol 1993;168:508-13.
30. 30. Bronstein JM, Goldenberg RL. Practice variation in the use of corticosteroids: a comparison of eight data sets. Am J Obstet Gynecol 1995;173:296-8.